Healthy Subjects Clinical Trial
— COCOFATOfficial title:
Effects of Chronic Intake of High in Flavonols Cocoa on Body Composition, Adipokines and Exercise Performance
Verified date | September 2019 |
Source | Universidad Europea de Madrid |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The decrease in body fat percentage improves exercise performance, reducing race time. The intake of cocoa improves the body fat composition in obese and diabetic people by improving their cardiovascular disease risk factors. Although epidemiological studies indicate that healthy subjects who consume cocoa have lower body fat composition, there is no study indicating whether cocoa improves fat composition in athletes. The aim of the study was to determine if the intake of cocoa rich in flavonoids improves the fat composition of athletes, modifying the systemic levels of adipokines (folistatin, myostatin and leptin), resulting in an improvement of physical performance.
Status | Completed |
Enrollment | 40 |
Est. completion date | April 1, 2019 |
Est. primary completion date | February 20, 2019 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | Male |
Age group | 18 Years to 50 Years |
Eligibility |
Inclusion Criteria: - Men. - Age between 18 and 50 years - Aerobic power of oxygen consumption greater than or equal to 55 mL / kg / min Exclusion Criteria: - Intake of chronical medication. - Intake any type of nutritional or ergogenic supplements. - Vegetarian or vegan diet - Smoke. - Any diagnosed disease at the time of inclusion or during the study |
Country | Name | City | State |
---|---|---|---|
Spain | Jose Ángel García Merino | Villaviciosa De Odón | Madrid |
Lead Sponsor | Collaborator |
---|---|
Universidad Europea de Madrid | Ministerio de Economía y Competitividad, Spain |
Spain,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change of body fat mass at 10 weeks | Energy X-ray absorptiometry (DEXA). | Fat mass was analyzed at the beginning (baseline time = 0) and after 10 weeks of intervention | |
Secondary | Change of lean mass at 10 weeks | Energy X-ray absorptiometry (DEXA). | Lean mass was analyzed at the beginning (baseline time) and after 10 weeks of intervention | |
Secondary | Change in Sport performance test at 10 weeks | Assessment of maximal aerobic capacity by treadmill test | Sport performance was analyzed at the beginning (baseline time) and after 10 weeks of intervention | |
Secondary | Change in Sport performance test 2 at 10 weeks | Measurement of the time that the sportsmen spend running one kilometer at the maximum speed. | Sport performance was analyzed at the beginning (baseline time and after 10 weeks of intervention | |
Secondary | Change from baseline of adipokines at 10 weeks | Myostatin and Follistatin levels were measured in plasma | Myostatin and Follistatin were analyzed at the beginning and at the end of the 10-week intervention. | |
Secondary | Change from baseline of leptin | leptin levels were measured in plasma by ELISA | Leptin was analyzed at the beginning and at the end of the 10-week intervention. | |
Secondary | Change in Dietary habits at 10 weeks | Food Frequency Questionnaire. Consumption data were obtained for 93 foods. These data were entered into the DietSource software 3.0 (Novartis, Barcelona, Spain) to transform food data into percentage of carbohydrates, percentage of proteins and percentage of fat in the diet. | Diet was analyzed at the beginning (baseline dose) and after 10 weeks of intervention. | |
Secondary | Change in Dietary habits 2 at 10 weeks | 24h recall questionnaire. This questionnaire was carried out 3 times on different days (2 weekdays and one weekend day) at the beginning (baseline) and after 10 weeks of intervention.These data were entered into the DietSource software 3.0 (Novartis, Barcelona, Spain) to transform food data into percentage of carbohydrates, percentage of proteins and percentage of fat in the diet. | Diet was analyzed at the beginning (baseline dose) and after 10 weeks of intervention. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05483998 -
A Study to Evaluate Single and Multiple Doses of TLC-2716 in Healthy Participants
|
Phase 1 | |
Recruiting |
NCT02417714 -
Prospective Evaluation of Next Generation CT Reconstruction (NextGenIR)
|
||
Recruiting |
NCT02235012 -
Cognitive Biases Under Ketamine
|
N/A | |
Completed |
NCT05088343 -
Effect of Hetrombopag on the Pharmacokinetics of Rosuvastatin in Healthy Subjects
|
Phase 1 | |
Completed |
NCT04418973 -
Analysis of Breath Volatile Organic Compounds After Dyspnea Induced in the Healthy Subject.
|
N/A | |
Not yet recruiting |
NCT06248801 -
Vildagliptin and Metformin Tablets 50/1000 mg Relative to GALVUS MET (50mg/1000 mg) Tablets
|
Phase 1 | |
Terminated |
NCT04068259 -
Single Ascending Dose Study of PBI-4547 in Healthy Subjects
|
Phase 1 | |
Completed |
NCT03279302 -
Trial to Evaluate the PK Profile of Glepaglutide (ZP1848) After a Single IV and After Multiple SC Injections in Healthy Subjects
|
Phase 1 | |
Not yet recruiting |
NCT06233162 -
Febuxostat 80 mg Tablets Relative to Feburic® 80 mg Tablets
|
Phase 1 | |
Recruiting |
NCT04159844 -
Evaluation of the Stiffness and Pressure Applied on the Lower Leg by a New Compression Bandage on Healthy Subjects
|
N/A | |
Completed |
NCT06137911 -
Evaluation of Safety, Tolerability & Pharmacokinetics of JYP0061 in Healthy Adults.
|
Phase 1 | |
Completed |
NCT04849286 -
Measurement of HTL0016878 in Cerebrospinal Fluid
|
Phase 1 | |
Not yet recruiting |
NCT06233227 -
Dutasteride Soft Capsule 0.5 mg Relative to Avodart 0.5 mg Soft Capsule
|
Phase 1 | |
Completed |
NCT04096157 -
A Study to Assess Isavuconazole Following a Single Dose of Isavuconazonium Sulfate Intravenous Solution Via Nasogastric (NG) Tube Compared to a Single Dose of Oral Capsules Under Fasting Conditions in Healthy Participants
|
Phase 1 | |
Completed |
NCT01200368 -
Trial Evaluating a 13-valent Pneumococcal Conjugate Vaccine Given With Diphtheria, Tetanus, and Acellular Pertussis Vaccine (DTaP) in Healthy Japanese Infants
|
Phase 3 | |
Recruiting |
NCT05805033 -
Peri-Implant Soft Tissue Integration in Humans: Influence of Material
|
N/A | |
Completed |
NCT04027803 -
Comparative Study of Pharmacokinetics, Pharmacodynamics, Safety, and Immunogenicity of Single Intravenous Doses of BCD-148 and Soliris®
|
Phase 1 | |
Recruiting |
NCT03467880 -
Multicenter Study of Impulse Oscillometry in Chinese
|
N/A | |
Completed |
NCT02903095 -
Single Ascending Dose Study of TD-1439 in Healthy Subjects
|
Phase 1 | |
Active, not recruiting |
NCT02341508 -
A Phase 1a, Double-Blind, Placebo-Controlled, Single Ascending Dose Study to Evaluate Lpathomab in Healthy Volunteers
|
Phase 1 |